Antony Loebel Selected Research

Psychomotor Agitation (Akathisia)

9/2020	Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
1/2020	Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.
8/2017	Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
1/2016	Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts.
2/2014	Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
2/2014	Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
2/2014	Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
5/2013	Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
9/2011	Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Antony Loebel Research Topics

Disease

59	Schizophrenia (Dementia Praecox) 08/2023 - 02/2004
36	Bipolar Disorder (Manic Depressive Psychosis) 01/2023 - 01/2007
16	Weight Gain 01/2022 - 01/2007
13	Sleepiness 01/2023 - 05/2012
13	Major Depressive Disorder (Major Depressive Disorders) 12/2020 - 07/2007
12	Psychotic Disorders (Schizoaffective Disorder) 01/2020 - 04/2006
9	Psychomotor Agitation (Akathisia) 09/2020 - 09/2011
8	Nausea 10/2021 - 05/2012
6	Body Weight (Weight, Body) 12/2021 - 02/2013
6	Sleep Initiation and Maintenance Disorders (Insomnia) 10/2021 - 05/2012
6	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021 - 11/2015
6	Mania (Manias) 12/2020 - 01/2007
4	Headache (Headaches) 10/2021 - 05/2012
3	Weight Loss (Weight Reduction) 01/2017 - 05/2009
2	Binge-Eating Disorder (Binge Eating Disorder) 10/2021 - 01/2020
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2020 - 01/2020
2	Overweight 01/2020 - 11/2015
2	Vomiting 08/2017 - 04/2016
2	Movement Disorders (Movement Disorder) 10/2008 - 01/2007
1	Cognitive Dysfunction 08/2023
1	Cataplexy 01/2023
1	Narcolepsy 01/2023
1	Mood Disorders (Mood Disorder) 01/2021
1	Insulin Resistance 10/2020
1	Inflammation (Inflammations) 10/2020
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2020
1	Bulimia (Binge Eating) 01/2020
1	Parkinsonian Disorders (Parkinsonism) 01/2020
1	Lipid Metabolism Disorders (Metabolism Disorders, Lipid) 06/2017
1	Diabetes Mellitus 06/2017
1	Body-Weight Trajectory 01/2017
1	Substance-Related Disorders (Drug Abuse) 12/2016
1	Hyperglycemia 12/2016
1	Obesity 12/2016
1	Autistic Disorder (Autism) 04/2016
1	Mental Disorders (Mental Disorder) 12/2015
1	Tremor (Tremors) 02/2014
1	Treatment-Resistant Depressive Disorder 07/2007

Drug/Important Bio-Agent (IBA)

80	Lurasidone Hydrochloride FDA Link 01/2023 - 06/2009
40	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 02/2004
24	ziprasidone (Geodon)FDA Link 11/2021 - 02/2004
20	Quetiapine Fumarate (Seroquel)FDA Link 01/2022 - 04/2013
13	Olanzapine (Zyprexa)FDA Link 11/2021 - 02/2004
13	Risperidone (Risperdal Consta)FDA LinkGeneric 09/2020 - 02/2004
8	Aripiprazole (Abilify)FDA Link 11/2021 - 11/2007
7	ProlactinIBA 01/2022 - 01/2009
7	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2009
7	4- (3,4- dichlorophenyl)- 1,2,3,4- tetrahydronaphthalen- 1- amineIBA 10/2021 - 11/2015
7	Valproic Acid (Depakote)FDA LinkGeneric 01/2017 - 01/2015
7	LithiumIBA 01/2017 - 01/2015
6	CholesterolIBA 01/2022 - 09/2009
6	Antidepressive Agents (Antidepressants)IBA 01/2021 - 04/2015
5	Triglycerides (Triacylglycerol)IBA 01/2022 - 09/2009
4	Trace amine-associated receptor 1IBA 08/2023 - 01/2020
4	SEP-363856IBA 08/2023 - 01/2020
4	Serotonin (5 Hydroxytryptamine)IBA 08/2023 - 01/2020
4	LipidsIBA 08/2017 - 02/2013
4	Haloperidol (Haldol)FDA LinkGeneric 08/2010 - 04/2006
3	Dopamine (Intropin)FDA LinkGeneric 08/2023 - 09/2013
3	C-Reactive ProteinIBA 10/2020 - 10/2018
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2018
2	Amisulpride (Solian)IBA 01/2022 - 01/2021
2	cariprazineIBA 11/2021 - 01/2021
2	Insulin (Novolin)FDA Link 08/2014 - 02/2013
1	5-HT1A Serotonin ReceptorIBA 08/2023
1	mesoglycanIBA 01/2022
1	antiarrhythmic peptide (AAP)IBA 11/2021
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2021
1	HDL LipoproteinsIBA 10/2020
1	Paliperidone Palmitate FDA Link 09/2020
1	asenapine FDA Link 09/2020
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2020
1	brexpiprazoleIBA 01/2018
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2018
1	Clozapine (Clozaril)FDA LinkGeneric 01/2017
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 01/2017
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 02/2016
1	3,4-dihydroxyphenylglycolIBA 02/2016
1	Therapeutic UsesIBA 01/2016
1	LDL CholesterolIBA 02/2014
1	olanzapine-fluoxetine combination (Symbyax)FDA Link 02/2014
1	A 7 (A-7)IBA 05/2009

Therapy/Procedure

12	Therapeutics 01/2021 - 05/2009
1	Precision Medicine 10/2018
1	Glycemic Control 08/2017
1	Length of Stay 01/2017
1	Patient Readmission 01/2016
1	Secondary Prevention 06/2013
1	Duration of Therapy 05/2009